Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Future Innovation in Oncology: Update Bulletin # 1 [October 2018]

Product Code:
596201271
Publication Date:
October 2018
Format:
PDF
Price:
$1,095

Topics covered include in this update bulletin include: Phase I data for novel RET inhibitor, LOXO-292 (Loxo) in patients with NSCLC and thyroid cancer; Jounce Therapeutics’ presentation of Phase I/II data for its ICOS agonist, JTX-2011,from the ICONIC trial;data from the ILLUMINATE-204 trial of the combination of TLR-9 agonist tilsotolimod (Idera Pharmaceuticals) in combination with Yervoy (ipilimumab; BMS); the announcement from BMS and Nektar Therapeutics that they will be moving their drug combination of Opdivo (nivolumab) with NKTR-214 into late-stage development for a number of tumour types; Iovance Pharma’s announcement that they will present data for their autologous TIL (tumour infiltrating lymphocyte)-based programme at an upcoming conference.

Business Questions:

• What are KOLs’ opinions of LOXO-292 data in patients with NSCLC, thyroid and pancreatic cancer?
• How many patients are estimated to have RET-altered mutations and to what extent is testing for RETmutations routine practice?
• To what extent is there an unmet need for new therapy options in RET-altered cancers?
• How do the experts view the ICONIC trial data for JTX-2011?
• What are KOLs’ responses to the tilsotolimod-Yervoy combination in metastatic melanoma?
• What do KOLs predict for the future development of NKTR-214-Opdivo combination?
• How does TIL therapy compare to CAR T-cell therapy in solid tumours and what are the potential drawbacks of such an approach?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved